Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Epigenomics AG announced the financial results for the first quarter of the FY 2019.
Four biotech companies began trading on the Nasdaq this morning. Here’s a look at today’s launches and one rumored IPO.
Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.
Under the terms of the deal, Pfizer will pay $340 million up front with another $470 million in payments contingent on milestones for the development and commercialization of TA-46 for the treatment of achondroplasia.
MorphoSys AG reports results for the first quarter of 2019.
Retrophin, Inc. reported its first quarter 2019 financial results and provided a corporate update.
Vericel Corporation reported financial results for the first quarter ended March 31, 2019, and recent business highlights.
ADL Bionatur Solutions advances the results of selected key performance indicators for the first quarter of 2019 ending March 31, 2019.
Esperion announced that the company will host an analyst and investor day on Thursday, May 30, 2019, beginning at 9:00 a.m. Eastern Time.
Strong Crysvita® (burosumab) Launch Continues with Approximately 730 Patients on Reimbursed Commercial Therapy in the United States